FDA+ roundup: Spring regulatory agenda looks to finish off Cures implementation; GAO digs into medical countermeasures
The Biden administration released its Spring regulatory agenda, offering up plans on which proposed and final rulemakings will be coming down the pike in the not-too-distant future.
For the FDA, many of the draft and final rules are repeats, although the agency will look to clear its plate of remaining 21st Century Cures Act obligations, which have been in the works since 2016.
For instance, although Section 3023 of the Cures Act has a Dec. 2019 statutory deadline, the agenda shows the FDA is still hoping to release two proposed rules related to that part of the bill this September.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.